Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Nanobiotix S.A. ADR (NQ: NBTX )

5.090 -0.130 (-2.49%)
Streaming Delayed Price Updated: 2:05 PM EDT, Oct 9, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Nanobiotix S.A. ADR

< Previous 1 2 3 4 5 Next >
NANOBIOTIX Announces Termination of Liquidity Contract and Publishes End of Contract Statement
From Nanobiotix S.A.
Via GlobeNewswire
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
NANOBIOTIX to Present at the 5th Annual Evercore ISI HealthCONx Conference
From Nanobiotix S.A.
Via GlobeNewswire
NANOBIOTIX Announces Recommended Phase 2 Dose for NBTXR3 in Pancreatic Cancer
From Nanobiotix S.A.
Via GlobeNewswire
NANOBIOTIX Reports Updated Phase 1 Anti-PD-1 Combination Data That May Support the Immune Stimulation Potential of Radioenhancer NBTXR3 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer
Data to be discussed during Nanobiotix Q3 Earnings Call at 8:00AM EST 
From Nanobiotix S.A.
Via GlobeNewswire
NANOBIOTIX Provides Third Quarter 2022 Operational and Financial Update
From Nanobiotix S.A.
Via GlobeNewswire
NANOBIOTIX Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
NANOBIOTIX Appoints Renowned Global Experts to Comprehensive Scientific Advisory Board for Potential First-in-Class Radioenhancer NBTXR3
Multidisciplinary board includes twelve (12) experts from the United States and Europe that will support the development of lead therapeutic candidate NBTXR3 
From Nanobiotix S.A.
Via GlobeNewswire
NANOBIOTIX to Present at the Jefferies London Healthcare Conference
From Nanobiotix S.A.
Via GlobeNewswire
NANOBIOTIX to Announce Third Quarter 2022 Financial Results on November 9, 2022
Conference Call and Webcast to be Held at 8:00 AM ET / 2:00 PM CET on November 10, 2022 
From Nanobiotix S.A.
Via GlobeNewswire
NANOBIOTIX Executes Definitive Agreement to Restructure Existing Loan With the European Investment Bank
From Nanobiotix S.A.
Via GlobeNewswire
Nanobiotix: Voting Rights and Shares Capital of the Company
From Nanobiotix
Via Business Wire
Nanobiotix Provides Business Update and Reports Financial Results for the First Half of 2022
From Nanobiotix
Via Business Wire
Nanobiotix to Announce Half Year 2022 Financial Results on September 28, 2022
From Nanobiotix
Via Business Wire
Nanobiotix Establishes Recommended Dose for Planned Registrational Study Evaluating NBTXR3 Plus Anti-PD-1 for Patients With Metastatic Head and Neck Cancer Resistant to Prior Immunotherapy
From Nanobiotix
Via Business Wire
Nanobiotix Announces Agreement in Principle to Restructure Existing Loan Agreement With European Investment Bank, Extending Operating Runway Into Q1 2024
From Nanobiotix
Via Business Wire
Nanobiotix: Voting Rights and Shares Capital of the Company
From Nanobiotix
Via Business Wire
NANOBIOTIX and LianBio Announce First Patient Enrolled in Asia in Phase 3 NANORAY-312 Trial Evaluating NBTXR3 for the Treatment of Head and Neck Cancer
From NANOBIOTIX
Via Business Wire
NANOBIOTIX Co-Founder and CEO Laurent Levy Named to 2022 PharmaVoice 100 List of Most Inspiring People in Life Sciences
From NANOBIOTIX
Via Business Wire
Nanobiotix to Present During the H.C. Wainwright Global Investment Conference in September 2022
From NANOBIOTIX
Via Business Wire
NANOBIOTIX: Voting Rights and Shares Capital of the Company
From Nanobiotix
Via Business Wire
Half-year Report on the Nanobiotix Liquidity Contract With Gilbert Dupont
From Nanobiotix
Via Business Wire
NANOBIOTIX: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
From Nanobiotix
Via Business Wire
NANOBIOTIX: New Data Featuring NBTXR3 Plus Chemoradiation and in the Preoperative Setting Support Broad Applicability for Head and Neck Cancer and Other Solid Tumor Indications
From NANOBIOTIX
Via Business Wire
NANOBIOTIX Annual Shareholders’ General Meeting to Be Held on June 23, 2022
From Nanobiotix
Via Business Wire
CORRECTING and REPLACING: NANOBIOTIX Provides First Quarter Operational and Financial Update
From Nanobiotix
Via Business Wire
NANOBIOTIX Provides First Quarter Operational and Financial Update
From Nanobiotix
Via Business Wire
NANOBIOTIX to Present During the Jefferies Healthcare Conference in June 2022
From Nanobiotix
Via Business Wire
NANOBIOTIX to Participate in Two Upcoming Investor Conferences
From Nanobiotix
Via Business Wire
Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
From Nanobiotix
Via Business Wire
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.